Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Incyte (INCY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$118.01-3.94%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
8.50 → 8.16 EPS · FY ending Dec 31, 2027 · 15 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 15 to 15; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for INCY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage R&D and SG&A expenses within $3.21B to $3.38B in 2026 | A supporting condition in Incyte's published investment case. The stated target is R&D + SG&A expenses <= $3.38B. | Intact | expenses exceed $3.38B in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a commercial growth and pipeline-execution story, with recent financial performance still strong but the broader thesis now in a watch state. Management has delivered on sales growth priorities, while evidence for pipeline progress is mixed because milestones do not establish clinical outcomes.
The valuation evidence is mixed: one measure points to INCY being cheap versus peers, while another shows a 66% premium to peers and the value factor is rated expensive. The priced-in tag is justified, with low fragility, but the expectations gap is negative; overall, the evidence does not show a clear margin between expectations and results.
Near term, recent results show growth in total net sales, Opzelura, and Hematology and Oncology, and management raised 2026 guidance for both product categories. Pipeline spending and development activity are advancing, but clinical outcomes remain uncertain; momentum and company quality scores also fell after fresh earnings. The near-term miss risk is rated low, though the evidence notes a high-miss-rate industry and a deep miss in recent history.
The multi-year thesis depends on continued growth across marketed products and progress in late-stage programs, alongside evidence that pipeline spending leads to clinical progress. Near term, a guidance reversal after the recent increase would damage credibility, while continued strength from Healthcare peers could support sector momentum. A weakening jobs trend is also flagged as a risk to sector sentiment.
Over the next 1 to 3 years, INCY’s thesis has support from commercial growth and raised guidance, but pipeline outcomes, easing recent momentum, and an expensive-versus-peers valuation remain important constraints. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The recent acquisition of Vega Therapeutics expands the pipeline and supports future growth. |
| Intact |
| acquisition integration delays or pipeline setbacks reported |
Qualitative: Vega acquisition completed 2026-07-06; no delays reported Vega acquisition completed July 2026. Pipeline advancing with positive Phase 2 data and sales growth. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Growth in Jakafi, Opzelura, and Hematology/Oncology sales | Jakafi sales rose 7% to $758M and Opzelura sales grew 20% to $143M. | Intact | any product line growth falls below half of target growth rates | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Total net sales growth to at least $3.29B in 2026 | Incyte grows total net sales 20% year-over-year to $1.27B in Q1 2026. | Intact | total net sales fall below $3.2B in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$8.87 → $8.16 · observed estimates
$6.19B → $6.27B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $8.87 | $6,186,155,379 | 10 / 11 |
| 2026-07-25 | $9.01 | $6,205,129,210 | 10 / 11 |
| 2026-07-26 | $9.01 | $6,205,129,210 | 10 / 11 |
| 2026-07-27 | $9.00 | $6,191,621,912 | 9 / 11 |
| 2026-07-28 | $8.89 | $6,192,021,912 | 9 / 11 |
| 2026-07-29 | $9.04 | $6,195,826,330 | 12 / 13 |
| 2026-07-30 | $8.72 | $6,216,478,103 | 11 / 14 |
| 2026-07-31 | $8.60 | $6,202,010,612 | 13 / 16 |
| 2026-08-01 | $8.60 | $6,202,010,612 | 13 / 16 |
| 2026-08-02 | $8.60 | $6,202,010,612 | 13 / 16 |
| 2026-08-03 | $8.60 | $6,202,010,612 | 13 / 16 |
| 2026-08-04 | $8.79 | $6,222,706,330 | 18 / 19 |
| 2026-08-05 | $8.88 | $6,255,376,010 | 18 / 20 |
| 2026-08-06 | $8.88 | $6,255,376,010 | 18 / 20 |
| 2026-08-07 | $8.63 | $6,218,166,294 | 13 / 16 |
| 2026-08-08 | $8.63 | $6,218,166,294 | 13 / 16 |
| 2026-08-09 | $8.88 | $6,255,376,010 | 18 / 20 |
| 2026-08-10 | $8.63 | $6,218,166,294 | 13 / 16 |
| 2026-08-12 | $8.63 | $6,218,166,294 | 13 / 16 |
| 2026-08-13 | $8.88 | $6,255,226,010 | 18 / 20 |
| 2026-08-14 | $8.63 | $6,218,166,294 | 13 / 16 |
| 2026-08-15 | $8.63 | $6,218,166,294 | 13 / 17 |
| 2026-08-16 | $8.63 | $6,218,166,294 | 13 / 17 |
| 2026-08-17 | $8.63 | $6,218,166,294 | 13 / 17 |
| 2026-08-18 | $8.63 | $6,218,166,294 | 13 / 17 |
| 2026-08-19 | $8.63 | $6,218,166,294 | 13 / 17 |
| 2026-08-20 | $8.59 | $6,226,016,033 | 13 / 17 |
| 2026-08-21 | $8.59 | $6,226,016,033 | 13 / 17 |
| 2026-08-22 | $8.54 | $6,232,765,365 | 14 / 17 |
| 2026-08-23 | $8.54 | $6,232,765,365 | 14 / 17 |
| 2026-08-24 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-08-25 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-08-26 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-08-27 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-08-28 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-08-29 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-08-30 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-08-31 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-09-01 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-09-02 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-09-03 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-09-04 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-09-05 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-09-06 | $8.54 | $6,232,765,365 | 14 / 18 |
| 2026-09-07 | $8.54 | $6,232,765,365 | 15 / 18 |
| 2026-09-08 | $8.54 | $6,232,765,365 | 15 / 18 |
| 2026-09-09 | $8.54 | $6,232,765,365 | 15 / 18 |
| 2026-09-10 | $8.54 | $6,232,765,365 | 15 / 18 |
| 2026-09-11 | $8.54 | $6,232,890,365 | 15 / 18 |
| 2026-09-12 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-13 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-14 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-15 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-16 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-17 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-18 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-19 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-20 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-21 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-22 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-23 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-24 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-25 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-26 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-27 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-28 | $8.54 | $6,232,757,032 | 15 / 18 |
| 2026-09-29 | $8.60 | $6,233,286,157 | 15 / 18 |
| 2026-09-30 | $8.60 | $6,233,286,157 | 15 / 18 |
| 2026-10-01 | $8.60 | $6,233,286,157 | 15 / 18 |
| 2026-10-02 | $8.57 | $6,233,411,149 | 15 / 18 |
| 2026-10-03 | $8.50 | $6,229,523,204 | 15 / 18 |
| 2026-10-04 | $8.50 | $6,229,523,204 | 15 / 18 |
| 2026-10-05 | $8.50 | $6,229,523,204 | 15 / 18 |
| 2026-10-06 | $8.47 | $6,224,972,246 | 15 / 18 |
| 2026-10-07 | $8.47 | $6,224,972,246 | 15 / 18 |
| 2026-10-08 | $8.47 | $6,224,972,246 | 15 / 18 |
| 2026-10-09 | $8.46 | $6,226,481,746 | 15 / 18 |
| 2026-10-10 | $8.44 | $6,224,961,455 | 15 / 18 |
| 2026-10-11 | $8.44 | $6,224,961,455 | 15 / 18 |
| 2026-10-12 | $8.44 | $6,224,961,455 | 15 / 18 |
| 2026-10-13 | $8.21 | $6,220,376,188 | 15 / 18 |
| 2026-10-14 | $8.19 | $6,218,120,538 | 15 / 18 |
| 2026-10-15 | $8.19 | $6,218,120,538 | 15 / 18 |
| 2026-10-16 | $8.17 | $6,213,628,359 | 15 / 18 |
| 2026-10-17 | $8.17 | $6,213,628,359 | 15 / 18 |
| 2026-10-18 | $8.12 | $6,213,627,109 | 15 / 18 |
| 2026-10-19 | $8.12 | $6,213,627,109 | 15 / 18 |
| 2026-10-20 | $8.12 | $6,213,626,872 | 15 / 18 |
| 2026-10-21 | $8.12 | $6,213,626,872 | 15 / 18 |
| 2026-10-22 | $8.13 | $6,215,652,805 | 15 / 18 |
| 2026-10-23 | $8.13 | $6,215,652,805 | 15 / 18 |
| 2026-10-24 | $8.13 | $6,215,652,805 | 15 / 18 |
| 2026-10-25 | $8.13 | $6,215,652,805 | 15 / 18 |
| 2026-10-26 | $8.13 | $6,215,652,805 | 16 / 18 |
| 2026-10-27 | $8.13 | $6,215,652,805 | 16 / 18 |
| 2026-10-28 | $8.13 | $6,215,505,268 | 16 / 19 |
| 2026-10-29 | $8.13 | $6,196,429,018 | 16 / 19 |
| 2026-10-30 | $8.19 | $6,243,726,795 | 16 / 19 |
| 2026-10-31 | $8.19 | $6,248,815,732 | 15 / 17 |
| 2026-11-01 | $8.19 | $6,248,815,732 | 15 / 17 |
| 2026-11-02 | $8.19 | $6,248,815,732 | 15 / 17 |
| 2026-11-03 | $8.16 | $6,274,826,857 | 15 / 18 |
| 2026-11-04 | $8.16 | $6,274,826,857 | 15 / 18 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 14 Hold · 2 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 10 recorded
3 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.